Drug manufacturers (sanofi-aventis excluded!) are keen to challenge Ambien's (zolpidem's) popularity as a prescription sleep aid. Their latest hope is a drug currently known as Lorediplon.
Lorediplon is a non-benzodiazapine that is hoping to compete with similar drugs such as Ambien (zolpidem), Sonata (Zaleplon) and Lunesta (eszopiclone). In a phase I clinical trial, Lorediplon appeared to match or even exceed zolpidem when measuring sleep duration and sleep quality.
For the purposes of the trial, 34 adults were given Lorediplon, zolpidem or a placebo and were told to go to bed five hours before their normal sleep time and remain in bed until the early morning.
In addition to the comparative effects of Lorediplon with zolpidem, the new drug appeared to be well tolerated without any residual effects when measured 14 hours after taking the drug.
The drug manufacturer is hoping that Lorediplon could become the best-in-class non-benzodiazapine for insomnia.
Our thoughts? New drug advances are welcome, but we'd rather see more emphasis placed on dealing with the root causes of insomnia rather than masking its symptoms.
Of course, insomnia isn't always a symptom - so drugs do have their place, but we'd rather see more investment in CBT, which has proven to be safer and more effective when it comes to treating insomnia.
Source: Medical News Today
Last updated: April 17, 2012